ClinicalTrials.gg
Active, not recruitingNCT07502534Updated May 15, 2026

A Clinical Study Comparing the Bioequivalence of IBI3027 and DUPIXENT®(Dupilumab) in Healthy Chinese Volunteers

A Phase 1 interventional study of IBI3027 and DUPIXENT® (dupilumab) in Healthy Volunteers, sponsored by Innovent Biologics (Suzhou) Co. Ltd.. Active, not recruiting at 1 site in China. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-15.

Sponsored by Innovent Biologics (Suzhou) Co. Ltd. (part of Innovent Biologics, Inc.) · Phase 1, Interventional, and Treatment

How we know · 4 judgments

From the registry’s dates

  • Primary completion was expected by Jul 2026, 4 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Male
01

Study summary

This study is a multicenter, randomized, double-masked, parallel-group, reference-drug-controlled clinical trial of IBI3027 in healthy male volunteers.

Healthy volunteers will be randomly assigned in a 1:1 ratio to receive either IBI3027 or DUPIXENT?. The dosage for both groups is 300 mg. The entire study includes a 28-day screening period and a 56-day observation period (including 3 days of hospitalization). Randomization is stratified by body weight at baseline (D1) ≤ 70 kg vs. > 70 kg.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Innovent Biologics (Suzhou) Co. Ltd. is the lead sponsor of 199 studies on the registry; 46 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Follow the test procedures and voluntarily sign the form;
  2. Male individuals aged 18 to 45 years (inclusive of the boundary value);
  3. Weight between 63 and 75 kg (inclusive of the boundary value);
  4. Agree to take measures from the screening period to 120 days after the administration of the study drug.

Exclusion criteria

Exclusion criteria:

  1. Those with a history of severe, progressive, and uncontrolled diseases in the liver, kidneys, cardiovascular system, nervous/psychiatric system, gastrointestinal tract, respiratory system, urinary system, endocrine system, hematologic system, etc.;
  2. Individuals with a known history of recurrent or chronic infections, including but not limited to: chronic kidney infections, chronic thoracic infections (e.g., bronchiectasis), sinusitis, recurrent urinary tract infections, or infected open wounds, draining wounds, or skin infections;
  3. Those with a known history of tuberculosis or clinical manifestations suspected of tuberculosis (including but not limited to pulmonary tuberculosis, lymph node tuberculosis, tuberculous pleurisy, etc.), or those with a positive IGRA test result;
  4. Participants who had opportunistic infections within 180 days before screening (e.g., herpes zoster, active cytomegalovirus, Pneumocystis carinii, Histoplasma capsulatum, Aspergillus, Mycobacterium tuberculosis, etc.);
  5. Participants who had an acute infection history within 14 days before screening;
  6. Those with a known history of immune system diseases (e.g., thymic diseases, systemic lupus erythematosus);
  7. Those with a history of ;
  8. Participants with abnormal vital signs and physical examination findings during the screening period, as judged by the investigator;
  9. Participants with abnormal laboratory test results during screening, including blood routine (absolute white blood cells count\< 3.50×10\^9/L, or > 9.50×10\^9/L, \< 1.8×10\^9/L, count \< 100×10\^9/L, \< 100 g/L), urinalysis, blood biochemistry [ (ALT), Aspartate Amino Transferase (AST), Total (TBIL), Direct Bilirubin (DBIL) > 1.5× (ULN), Creatinine (Cr) > ULN], coagulation function or thyroid function as judged clinically significant by the investigator;
  10. Participants with abnormal chest X-ray (posteroanterior and lateral views) during the screening period, as judged clinically significant by the investigator;
  11. Individuals testing positive for (HIV) antibody, virus (HCV) antibody, syphilis antibody (either specific or non-specific), surface antigen (HBsAg), or hepatitis B e antigen (HBeAg);
  12. Those who had received IL-4Rα monoclonal antibody treatment in the past;
  13. Use of any medication (including traditional Chinese medicine and vitamins) within 14 days prior to screening, or use of any medication less than five half-lives before the administration of study drug, whichever is longer;
  14. Participants who had participated in other interventional clinical trials within 90 days before screening;
  15. Participants who had undergone major surgery or been hospitalized for illness within 90 days before screening;
  16. Participants who had lost blood, donated blood or received any blood product infusion ≥ 400 mL within 90 days before screening;
  17. Participants who had received within 180 days before screening, or were expected to receive live vaccines during the study period;
  18. Participants who had a history of alcohol and/or drug abuse within 1 year before screening, or those with positive drug screening results;
  19. Participants who had alcohol intake within 72 hours before screening or had a positive alcohol screening result;
  20. Those suspected or confirmed to have an allergic constitution, or who have had previous allergic reactions to drugs or foods, with a clear history of allergies and/or who are allergic to the test drug or its components;
  21. Participants who have a fertility plan from the screening period to 120 days after the administration of the drug, or who are unwilling to take the measures stipulated in the protocol during the trial;
  22. Those with disabilities, bedridden, dependent on a wheelchair, or unable to take care of themselves;
  23. Any other condition deemed by the investigator as rendering the participant unsuitable for participation in this clinical trial.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
180 participants (actual)

Study arms

  • Experimental
    IBI3027 treatment group

    The participants in this group will receive a 300 mg subcutaneous injection of IBI3027 on the first day.

    Drug: IBI3027

  • Active comparator
    DUPIXENT® (dupilumab) treatment group

    The participants in this group will receive a 300 mg subcutaneous injection of DUPIXENT® (Dupilumab Injection) on the first day.

    Drug: DUPIXENT® (dupilumab)

Interventions

  • DrugIBI3027

    The participants in IBI3027 treatment group will receive a 300 mg subcutaneous injection of IBI3027 on the first day.

  • DrugDupilumabStudies of DupilumabDupilumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The participants in DUPIXENT® (dupilumab) treatment group will receive a 300 mg subcutaneous injection of DUPIXENT® (Dupilumab Injection) on the first day.

06

What researchers measure

Primary outcomes

  1. Peak drug concentration (Cmax)

    Time frame: Days 1-57

  2. Area under the plasma concentration-time curve (AUC0-∞).

    Time frame: Days 1-57

Secondary outcomes

  1. Area under the plasma concentration-time curve (AUClast)

    Time frame: Days 1-57

  2. volume of distribution (V/F)

    Time frame: Days 1-57

  3. clearance rate (CL/F)

    Time frame: Days 1-57

  4. Anti-drug antibodies (ADA)

    Time frame: Days 1-57

  5. Neutralizing antibodies (NAb)

    Time frame: Days 1-57

  6. Elimination half-life (t1/2)

    Time frame: Days 1-57

  7. The number and proportion of serious adverse events related to the experimental drug

    Time frame: Days 1-57

  8. The number and proportion of treatment-related adverse events during the trial period

    Time frame: Days 1-57

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2026 (actual). Primary completion is estimated for Jul 2026, 2 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 26, 2026
First posted
Mar 31, 2026
StartActual
Apr 24, 2026
Primary completionEst.
Jul 7, 2026
CompletionEst.
Jul 7, 2026
Last update
May 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07502534
Responsible party
Sponsor
First posted
Mar 31, 2026
Start date
Apr 24, 2026
Primary completion
Jul 7, 2026 (estimated)
Completion
Jul 7, 2026 (estimated)
Last update
May 15, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion